We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+22.43%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$113M
AUM Growth
–
Cap. Flow
+$108M
Cap. Flow %
95.04%
Top 10 Hldgs %
61.67%
Holding
31
New
31
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$9.29M
2
BLUE
bluebird bio
BLUE
+$7.71M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.6M
4
SAGE
Sage Therapeutics
SAGE
+$7.08M
5
LOXO
Loxo Oncology, Inc
LOXO
+$6.75M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 77.28%
2 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
26
DELISTED
Juno Therapeutics, Inc.
JUNO
$769K 0.68%
+17,500
New +$868K
ATRA icon
27
Atara Biotherapeutics
ATRA
$77M
$660K 0.58%
+1,000
New +$756K
MDSO
28
DELISTED
Medidata Solutions, Inc.
MDSO
$493K 0.44%
+10,000
New +$440K
CRDF icon
29
Cardiff Oncology
CRDF
$72.7M
$378K 0.33%
+972
New +$381K
AGIO icon
30
CALL
Agios Pharmaceuticals
AGIO
$1.82B
$325K 0.29%
+5,000
New +$328K
FMI
31
CALL
DELISTED
Foundation Medicine, Inc.
FMI
$316K 0.28%
+15,000
New +$289K
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Casdin Capital, which disclosed 31 positions worth $113M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is Blueprint Medicines: 412,500 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, followed by Industrials.

  • Casdin Capital's largest Q4 2015 buy was Blueprint Medicines: 412,500 shares worth $10.9M.
  • Casdin Capital's ten largest holdings make up 62% of its $113M portfolio in Q4 2015.
  • Casdin Capital disclosed 31 positions in Q4 2015, its first 13F filing on record.

Based on Casdin Capital's 13F filing for Q4 2015, filed 8 Feb 2016.